Share on StockTwits

Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost purchased 10,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was purchased at an average price of $8.78 per share, for a total transaction of $87,800.00. Following the transaction, the chief executive officer now directly owns 2,012,377 shares in the company, valued at approximately $17,668,670. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of analysts have recently weighed in on OPK shares. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday, August 13th. They now have a $10.50 price target on the stock, down previously from $11.00. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $12.00.

Opko Health (NYSE:OPK) traded down 0.23% during mid-day trading on Wednesday, hitting $8.80. The stock had a trading volume of 215,929 shares. Opko Health has a one year low of $7.32 and a one year high of $12.95. The stock has a 50-day moving average of $8.94 and a 200-day moving average of $8.9. The company’s market cap is $3.777 billion.

Opko Health (NYSE:OPK) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.09) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.70 million. During the same quarter in the prior year, the company posted ($0.01) earnings per share. The company’s quarterly revenue was down 1.3% on a year-over-year basis. Analysts expect that Opko Health will post $-0.31 EPS for the current fiscal year.

OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.